Description

Simple

Clinical

Overview

Pristinamycin IIA is a macrolide antibiotic, a member of the streptogramin A group of antibiotics, and one component of pristinamycin. It is produced by Streptomyces graminofaciens and other bacteria.

Pharmacology

Indication

For the treatment of bacterial infections.

Pharmacodynamic

Information currently not available.

Mechanism of action

Virginiamycin M1 is a macrocyclic lactone antibiotic that acts syngeristically with the structurally unrelated cyclic depsipeptides more commonly known as the virginiamycins B (ostreogrycin B or streptogramin B) and S to inhibit peptide elongation. This is achieved by blocking formation of a peptide... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Virginiamycin M1
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with (R)-warfarin.
(S)-Warfarin
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with (S)-Warfarin.
4-hydroxycoumarin
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with 4-hydroxycoumarin.
Acenocoumarol
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Acenocoumarol.
BCG vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Virginiamycin M1.
Clorindione
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Clorindione.
Coumarin
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Coumarin.
Dicoumarol
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Dicoumarol.
Diphenadione
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Diphenadione.
Ethyl biscoumacetate
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Ethyl biscoumacetate.
Fluindione
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Fluindione.
Lactulose
The therapeutic efficacy of Lactulose can be decreased when used in combination with Virginiamycin M1.
Phenindione
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Phenindione.
Phenprocoumon
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Phenprocoumon.
Picosulfuric acid
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Virginiamycin M1.
Tioclomarol
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Tioclomarol.
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Virginiamycin M1.
Warfarin
The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Warfarin.
1 References
  1. 1 . US Biological Link